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www.cdatm.orgDyslipidemia, particularly the elevation of low-
density lipoprotein cholesterol (LDL-C) levels, is the
prerequisite for the occurrence and development of
plaque-based atherosclerotic cardiovascular disease
(ASCVD). LDL particles pass through the vascular
endothelium and become lodged within the walls of
blood vessels. Oxidative modification of LDL then oc-
curs under the action of extracellular matrix molecules,
followed by foam cell formation after macrophage
phagocytosis. Subsequently, there occur localized bio-
logical responses, mainly non-specific inflammation,
which further promotes LDL retention and atheroscle-
rotic lesion progression.
A large number of clinical studies has repeatedly
confirmed that, regardless of the medication type or
intervention method, as long as the plasma LDL-C level
is reduced, atherosclerotic lesions can be stabilized,
impeded, or alleviated. TheASCVD incidence aswell as
morbidity and mortality rates will also decrease signif-
icantly. Domestic and international dyslipidemia pre-
vention guidelines have all emphasized that LDL-C
plays a central and pathogenic role in ASCVD. Hence,
the prevention and control of ASCVD risk by decreasing* Tel.: þ86 13808426600.
E-mail address: zhaosp@medmail.com.cn.
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open access article under the CC BY-NC-ND license (http://creativecommblood LDL-C levels have been advocated.1e3 Therefore,
the dyslipidemia guidelines in China should still
recommend LDL-C as a primary interventional target.
In clinical practice, the majority of doctors
frequently set LDL-C reduction target to prevent
ASCVD. However, a few recent dyslipidemia guide-
lines published outside of China have recommended
not setting LDL-C reduction target1,2 since there has
been no evidence from randomized controlled trials
(RCT) to support specific LDL-C target. It is also
unknown which LDL-C target leads to the most sig-
nificant reduction in ASCVD risk. If a specific LDL-C
target is set, overtreatment with lipid-lowering drugs
might occur in patients with a particularly high base-
line LDL-C level; in contrast, the treatment might be
inadequate or deficient for patients with a baseline
LDL-C that is low or within normal limits.
Evidently, removing the LDL-C reduction target
will further cause a series of problems. First, doctors
themselves will misapprehend that the aim is not to
reduce LDL-C level but merely the use of certain
drugs; second, patient compliance with cholesterol-
lowering medication regimens will be seriously
compromised. From the perspective of benefitting from
lipid-lowering treatment, long-term adherence to
treatment is the most significant factor. It is only by
setting an LDL-C reduction target that doctors can
accurately evaluate treatment effectiveness and effec-
tively communicate with their patients, thereby
improving patient compliance with lipid-lowering drugElsevier B.V. on behalf of KeAi Communications Co., Ltd. This is an
ons.org/licenses/by-nc-nd/4.0/).
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eliminating the LDL-C reduction target in China that
will get more benefits.
Non-high-density lipoprotein cholesterol (non-HDL-
C) can also be used as a target in lipid-lowering therapy.
However, since clinicians in China generally have low
awareness of non-HDL-C, it would be inappropriate at
this stage to set it as the primary target, although it could
be considered a secondary target of lipid-lowering
therapy. Non-HDL-C is the sum of all cholesterol con-
tained in lipoproteins other thanHDLparticles, of which
LDL-C accounts for more than 70%. Other constituents
include chylomicrons, very low density lipoprotein, in-
termediate density lipoprotein, and cholesterol (a) par-
ticles in lipoprotein. Non-HDL-C may reflect the
cholesterol levels of all atherosclerosis pathogenic li-
poproteins and is calculated as: non-HDL-C ¼ total
cholesterol minus HDL-C.
The basic target value for blood lipids (referred to as
the target value) in lipid-lowering therapy should be
determined according to ASCVD risk. Since the optimal
target and virulence threshold values of LDL-C (or non-
HDL-C) have not been ascertained, the determination of
target value in lipid-lowering therapy could differ from
that of those during antihypertensive treatment and hy-
poglycemic therapy. The recommendation of lowering
LDL-C to a certain point (the target) is mainly based on
the consideration of the risk-benefit ratio: patients at
higher risk of future cardiovascular events would benefit
more; and reducing the LDL-C level will result in
greater cardiovascular clinical benefits, but the associ-
ated adverse reactions (from drugs or otherwise) will
also increase. Health economics is also an important
factor when determining the target.
All patients with a clinical diagnosis of ASCVD
(including acute coronary syndrome, stable coronary ar-
tery disease, post-revascularization, ischemic heart dis-
ease, ischemic stroke, transient cerebral ischemia attack,
peripheral atherosclerosis, etc)1 comprise a very-high-
risk group. As for the non-ASCVD population, risk
assessment requires implementation according to risk
factor number and severity. The population can then be
divided into high-risk,medium-risk, and low-risk groups,
according to which LDL-C reduction targets are set. The
LDL-C levels that trigger drug treatment and the LDL-C
targets differ widely among the different risk groups.
In the Chinese Guidelines for the Treatment and Pre-
vention of Dyslipidemia revision process, there was an
intense debate on whether the recommended LDL-C
reduction target for the high-risk group should be set at
LDL-C < 1.8 mmol/L (70 mg/dl) or < 2.0 mmol/L
(80mg/dl). Three rounds of voting were used to make thefinal formal decision of theLDL-C reduction target for the
very-high-risk group. The majority of the respondents
advocated for a target of <2.0 mmol/L (80 mg/dl) in the
first two rounds. However, in the final round, a small
majority supported the target of<1.8 mmol/L (70mg/dl).
This value is consistent with the recommended target in
most international lipid guidelines aswell as those inother
areas domestically such as in diabetes treatment. More
significantly, recently published results on statins and
ezetimibe combination therapy in a clinical trial4 showed
that, after a decrease in theLDL-C target from1.8mmol/L
(69.5mg/dl) to 1.4mmol/L (53.7mg/dl), the absolute risk
of cardiovascular events was further reduced by 2% and
the relative riskwas reducedby6.4%.However, the riskof
cardiovascular or all-cause mortality did not decrease.
Clearly, the clinical evidence is insufficient for all
recommended LDL-C targets. My personal opinion in
favor of recommending <2.0 mmol/L (80 mg/dl) as the
target is based on several reasons. First, the optimum
target value of blood lipids should be in Chinese adults is
unclear, and much controversy persists internationally
about how to determine the target value. There are even
cholesterol guidelines without recommended target
values. The 2007 Chinese Guidelines for the Treatment
and Prevention of Adult Dyslipidemia proposed that the
LDL-C target should be <2.0 mmol/L (80 mg/dl) in the
very-high-risk group,3 which can be used as an impor-
tant reference. Second, numerous studies have
confirmed that reducing the LDL-C target to<2.0mmol/
L (80 mg/dl) has already proven beneficial for ASCVD
or patients at high risk. (3) The clinical benefit from
lipid-lowering therapy is mainly from long-term
adherence to treatment. Therefore, patients' accessi-
bility and compliance is the key to achieving benefit.
Fourth, in clinical practice, although further reducing
LDL-C level could slightly increase the clinical benefits
for specific patients, it leads to increased individual and
public healthcare costs and limits the cost-effectiveness
of social healthcare. And fifth, animal lipid studies have
shown that atherosclerosis generally does not occur in
animals with an LDL-C < 2.0 mmol/L (80 mg/dl).
Direct measurement of atherosclerotic plaques using
serial intravascular ultrasonography showed that
achieving a serum LDL-C < 1.9 mmol/L (75 mg/dl)
could halt the progression of atherosclerosis.5
In addition, although many clinical trials6e10 have
demonstrated that high-dose statin therapy could further
lower the LDL-C level to promote a clinical benefit, in
most clinical trials, the mean LDL-C level in the inten-
sive lipid-lowering therapy group was 1.9e2.5 mmol/L
(72e95 mg/dl), indicating that even with the maximum
dose of statins (i.e. atorvastatin 80mg/d), only about half
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The benefit from intensive statin therapy is related to the
baseline LDL-C levels. Although all patients with a
baseline LDL-C  1.8 mmol/L (70 mg/dl) can benefit
from statin therapy, patients with a baseline LDL-
C < 2.0 mmol/L (80 mg/dl) received relatively smaller
benefits. More importantly, all of the results from clin-
ical studies of intensive statin therapy show that a
manifold increase in statins could reduce the ASCVD
incidence to a statistically significant level; but the ab-
solute benefit level was minor and all-cause mortality
had not decreased as well.11 These findings suggest that
although further reductions in LDL-C levels will offer
potential clinical benefit, the absolute margin of benefit
is smaller. Recommendations in the guideline were
proposed from the perspective of the overall population,
which considers the majority of patients with ASCVD.
Therefore, it should be very reasonable to recommend
LDL-C < 2.0 mmol/L (80 mg/dl) as the basic target. Of
course, depending on the clinical condition of particular
patients, if adverse drug reactions can be avoided and
personal expense is not an issue, the LDL-C level could
be reduced to a lower level.
In clinical practice, baseline LDL-C levels can
reach high or low extremes. In these cases, the treat-
ment strategy based on LDL-C target values should be
modified. For both cases, the LDL-C percentage
reduction strategy is feasible. Based on existing lipid-
lowering clinical trials, the majority of results from
those clinical studies suggested that lowering LDL-C
levels by 30e40% can produce a clinical benefit.
Since it is difficult for patients with higher baseline
LDL-C levels to achieve the target value using existing
drugs, the levels should be reduced by at least 40%.
Certain very-high-risk patients have a baseline LDL-C
level that is within the target range; thus, a reduction of
approximately 30% can be considered.References
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